“Is there a cure?”
There is no proven cure for CADASIL. Be cautious of online claims — including methylene blue. No study has shown methylene blue helps CADASIL in humans or animals; a widely-shared claim of “Harvard/Yale methylene blue CADASIL mouse research” does not exist and appears to be an AI-fabricated citation. Real hope is in early-stage gene-targeted research.
When you love someone with an incurable disease, you become a magnet for hope — and for false hope. We built this page because we went down one of those roads ourselves. A convincing summary claimed Harvard and Yale had shown methylene blue helped mice with CADASIL. We checked it carefully. The study doesn't exist. What happened was that an AI stitched two true-but-unrelated things together — a real paper about the compound in a generic cell-injury model, and a real list of the labs that build CADASIL mice — into a sentence that felt like a cure and wasn't. Methylene blue has zero CADASIL evidence, a failed dementia-drug track record, a mechanism that could theoretically worsen small-vessel constriction, and real danger for anyone on antidepressants. The lesson: when you're desperate, demand a source. Ask what was actually tested, in what.
- Methylene blue: no CADASIL trials or animal studies exist. Its most advanced neuro-derivative (LMTX/hydromethylthionine) failed Phase 3 in dementia. It inhibits the NO–cGMP pathway (vasoconstrictive) and carries serotonin-syndrome risk with SSRIs/SNRIs and hemolysis risk in G6PD deficiency.
- Where real hope is: gene-targeted approaches in preclinical development — antisense-oligonucleotide “exon-skipping” (potentially applicable to ~94% of mutations), base editing, and antibody immunotherapy — plus investigational cilostazol and stem-cell trials. None is FDA-approved yet.
- How to vet any claim: Was it tested in a cell, an animal, or a human? Is it a hypothesis or a result? Where's the primary source? What's the evidence grade?
Common questions
- Does methylene blue help CADASIL?
- There is no evidence it does, and real safety risks — do not self-dose, especially on antidepressants.
- Was there a Harvard/Yale study on methylene blue and CADASIL?
- No. That claim does not correspond to any real study and appears to be an AI-fabricated citation.
- Is there any promising CADASIL research?
- Yes — gene-targeted approaches (exon-skipping, base editing, immunotherapy) are in early development.